Cutaneous reactions in patients with chronic hepatitis c treated with peginterferon and ribavirin

Dermatology

Volumn 228, Issue 1, 2014, Pages 42-46

  Patrk, Ivana ^a   Morović, Miro ^a   Markulin, Anamarija ^a   Patrk, Jogen ^a  

^a GENERAL HOSPITAL ZADAR   (Croatia)

Author keywords

Chronic hepatitis C; Cutaneous reactions; Peginterferon; Ribavirin

Indexed keywords

PEGINTERFERON; RIBAVIRIN;

ADULT; ALOPECIA; ANEMIA; ARTICLE; DISEASE SEVERITY; ECZEMA; FEMALE; HEPATITIS C; HUMAN; LICHEN PLANUS; MAJOR CLINICAL STUDY; MALE; NEUTROPENIA; PRIORITY JOURNAL; PROSPECTIVE STUDY; PRURITUS; SKIN MANIFESTATION; THROMBOCYTOPENIA; THYROID DISEASE; XEROSIS; YOUNG ADULT; ADVERSE DRUG REACTION; ALOPECIA AREATA; DIABETES MELLITUS; DRUG USE; DYSTHYROIDISM; HEPATITIS C VIRUS GENOTYPE 1; HEPATITIS C VIRUS GENOTYPE 2; HEPATITIS C VIRUS GENOTYPE 3; HYPERTENSION; MENTAL DISEASE; SIDE EFFECT; TREATMENT DURATION;

ADULT; AGE FACTORS; ALOPECIA AREATA; ANTIVIRAL AGENTS; DRUG ERUPTIONS; DRUG THERAPY, COMBINATION; ECZEMA; FEMALE; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; MALE; POLYETHYLENE GLYCOLS; PROSPECTIVE STUDIES; PRURITUS; RECOMBINANT PROTEINS; RIBAVIRIN; TIME FACTORS;

EID: 84896721053     PISSN: 10188665     EISSN: 14219832     Source Type: Journal    
DOI: 10.1159/000353160     Document Type: Article

References (21)

1. Pearlman BL: Hepatitis C treatment update. Am J Med 2004; 117: 344-352.
2. Cacoub P, Renou C, Rosenthal E, Cohen P, Loury I, Loustaud-Ratti V, et al: Extrahepatic manifestation associated with hepatitis C virus infection. A prospective multicenter study of 321 patients. The GERMIVIC. Groupe d'Etude et de Recherche en Médecine Interne et Maladies Infectieuses sur le Virus de l'Hépatite C. Medicine (Baltimore) 2000; 79: 47-56.
3. Rebora A: Skin diseases associated with hepatitis C virus: facts and controversies. Clin Dermatol 2010; 28: 489-496.
4. Chang LW, Liranzo M, Berfeld WF: Cutaneous side effects associated with interferon-alpha therapy: a review. Cutis 1995; 56: 144.
5. Dalmau J, Pimentel CL, Puig L, Peramiquel L, Roe E, Alomar A: Cutaneous necrosis after injection of polyethylene glycol-modified interferon alfa. J Am Acad Dermatol 2005; 53: 62-66.
6. Sasseville D, Ghamdi WA, Khenazian SA: Interferon- induced cutaneous necrosis. J Cutan Med Surg 1999; 3: 320-323.
7. Arrue I, Saiz A, Ortiz-Romero PL, Rodriguez- Peralto JL: Lupus-like reaction to interferon at the injection site. Report of five cases. J Cutan Pathol 2007; 34: 18-21.
8. Vasguez-Lopez F, Manjon-Haces JA, Perez- Alvarez R, Perez-Oliva N: Eczema-like lesions and disruption of therapy in patients treated with interferon-alfa and ribavirin for chronic hepatitis C: the value of interdisciplinary assessment. Br J Dermatol 2004; 150: 1046-1047.
9. Mistry J, Shapiro RI, Crawford A: A review of adverse cutaneous drug reactions resulting from the use of interferon and ribavirin. Can J Gastroenterol 2009; 23: 677-683.
10. Gilhar A, Kalish RS: Alopecia areata: a tissue specific autoimmune disease of the hair follicle. Autoimmune Rev 2006; 5: 64-69.
11. Rosenstein ED, Warshauer BL: Alopecia areata and autoimmunity. J Am Acad Dermatol 2010; 62: 1065.
12. Forstbauer LM, Brockschmidt FF, Moskvina V, Herold C, Redler S, Herzog A, et al: Genome-wide pooling approach identifies SPATA5 as a new susceptibility locus for alopecia areata. Eur J Hum Genet 2012; 20: 326-332.
13. Jagielska D, Redler S, Brockschmidt FF, Herold C, Pasternack SM, Garcia Bartels N, et al: Follow-up study of the first genome-wide association scan in alopecia areata: IL13 and KIAA0350 as susceptibility loci supported with genome-wide significance. J Invest Dermatol 2012; 132: 2192-2197.
14. Jadali Z: Dermatologic manifestations of hepatitis C infection and the effect of interferon therapy: a literature review. Arch Iran Med 2012; 15: 43-48.
15. Ko HM, Hernandez-Prera JC, Zhu H, Dikman SH, Sidhu HK, Ward SC, et al: Morphologic features of extrahepatic manifestation of hepatitis C virus infection. Clin Dev Immunol 2012; 2012: 740138.
16. Protzer U, Ochsendorf FR, Leopolder-Ochsendorf A, Holtermuller KH: Exacerbation of lichen planus during interferon alfa-2a therapy for chronic active hepatitis C. Gastroenterology 1993; 104: 903-905.
17. Areias J, Velho GC, Cerqueira R, Barbedo C, Amaral B, Sanches M, et al: Lichen planus and chronic hepatitis C: exacerbation of the lichen under interferon-alpha-2a therapy. Eur J Gastroenterol Hepatol 1996; 8: 825-828.
18. Nagao Y, Kawaguchi T, Ide T, Kumashiro R, Sata M: Exacerbation of oral erosive lichen planus by combination of interferon and ribavirin therapy for chronic hepatitis C. Int J Mol Med 2005; 15: 237-241.
19. Nagao Y, Sata M: A retrospective case-control study of hepatitis C virus infection and oral lichen planus in Japan: association with mutations in the core and NS5A region of hepatitis C virus. BMC Gastroenterol 2012; 12: 31.
20. Jayavelu P, Sambandan T: Prevalence of hepatitis C and hepatitis B virus infection(s) in patients with oral lichen planus. J Pharm Bioallied Sci 2012; 4: 397-405.
21. Cacoub P, Bourliere M, Lubbe J, Dupin N, Buggisch P, Dusheiko G, et al: Dermatological side effects of hepatitis C and its treatment: patient management in the era of direct-acting antivirals. J Hepatol 2012; 56: 455-463.